Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Clinical trial NCT04882163 · WITHDRAWN

Trial details

NCT number: NCT04882163
Sponsor: Celgene
Status: WITHDRAWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Lymphoma, B-Cell

Start date: 2021-10-10
Primary completion: 2026-04-08
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.